Core Viewpoint - The recent decision by the National Medical Products Administration to cancel the registration certificates of 80 drugs, including commonly used medications, has led to significant price increases for certain products, such as the compound drug Taining suppository, which is now priced over 900 yuan for a box of six [1][3]. Group 1: Drug Cancellations - A total of 80 drugs, including popular medications like loratadine tablets and finasteride tablets, have been voluntarily deregistered by the manufacturers, indicating a strategic business decision rather than regulatory enforcement [3][5]. - The deregistered drugs are not exclusive products, allowing other companies with similar generic products to continue production and sales, which mitigates potential supply shortages [3][5]. - Over 40 of the deregistered drugs are produced by foreign companies, reflecting a response to the implementation of national centralized procurement policies that have significantly reduced drug prices [3][4]. Group 2: Market Impact - The deregistration of drugs like Taining suppository and loratadine tablets is attributed to a lack of sustainable raw material supply and the need for foreign companies to adjust their sales strategies to maintain profit margins [5][6]. - The cancellation of key oncology drugs, such as doxorubicin injection, highlights the challenges faced by original drug manufacturers due to the rapid growth of generic alternatives and ongoing price pressures from centralized procurement policies [5][6]. - The market for inhaled medications, such as salbutamol solutions, is also affected, as domestic companies are increasingly able to produce high-quality generics at competitive prices, further squeezing the market share of original products [6][7].